Zoeti a Aktie
178,20USD | -0,67USD | -0,37% |
WKN DE: A1KBYX / ISIN: US98978V1035
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 99,92 |
The Vanguard Group, Inc. | 8,94 |
Vanguard Group, Inc. (Subfiler) | 8,69 |
State Street Corp. | 4,38 |
State Farm Investment Management Corp. | 3,55 |
AllianceBernstein LP | 3,41 |
BlackRock Fund Advisors | 2,89 |
Vanguard Total Stock Market ETF | 2,85 |
Vanguard 500 Index Fund | 2,66 |
Geode Capital Management LLC | 2,31 |
BlackRock Institutional Trust Co. NA | 2,22 |
Managed Account Advisors LLC | 2,05 |
Capital Research & Management Co. (World Investors) | 1,48 |
Polen Capital Management LLC | 1,41 |
SPDR S&P 500 ETF Trust | 1,23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 10 600 | 11 300 | 12 100 | 13 800 | 14 100 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,59 | 0,59 | 0,64 | 0,59 | 0,61 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 4 748 | 6 611 | 6 930 | 7 506 | 6 343 |
Summe Anlagevermögen | 6 797 | 6 998 | 6 970 | 7 419 | 7 943 |
Summe Aktiva | 11 545 | 13 609 | 13 900 | 14 925 | 14 286 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 8 837 | 9 836 | 9 356 | 10 522 | 9 295 |
Summe Eigenkapital | 2 708 | 3 773 | 4 544 | 4 403 | 4 991 |
Summe Passiva | 11 545 | 13 609 | 13 900 | 14 925 | 14 286 |
Adresse
10 Sylvan Way, 07054 Parsippany | |
Telefon | +1 (973) 822-7000 |
Internet | http://www.zoetis.com |
Management
Abhay Nayak
Head-Strategy & Accelerated Growth Businesses |
Antoinette R. Leatherberry
Independent Director |
Frank A. D'Amelio
Independent Director |
Gavin D. K. Hattersley
Director |
Gregory Norden
Independent Director |
Jamie Andrew Brannan
Chief Commercial Officer |
Keith Sarbaugh
Executive VP, Chief Digital & Technology Officer |
Kristin C. Peck
Chief Executive Officer & Director |
Louise M. Parent
Independent Director |
Michael B. McCallister
Non-Executive Chairman |
Mike McFarland
Chief Medical Officer & Executive Vice President |
Paul M. Bisaro
Independent Director |
Rimma Driscoll
EVP, Head-Global Strategy & Business Development |
Robert J. Polzer
President-Research & Development, Executive VP |
Robert W. Scully
Independent Director |
Roxanne Lagano
Secretary, CHRO, Executive VP & General Counsel |
Sanjay Khosla
Independent Director |
Steven Frank
Head-Investor Relations |
Vanessa A. Broadhurst
Independent Director |
Wetteny Joseph
CFO, EVP & Head-Business Development |
William Dorsey
Head-US Operations |
Willie M. Reed
Independent Director |